VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Technical Scanner
RSI, Moving averages & volume momentum signals
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
Minervini — VCPContraction bases in Stage 2 uptrends
Minervini — Trend TemplateFull 8-rule Stage 2 screen
O'Neil — Cup with HandleBase breakouts with RS leadership
O'Neil — CANSLIM LeadersGrowth leaders with RS ≥ 85
Qullamaggie — High Tight FlagsPower plays after a large advance
Qullamaggie — Momentum Leaders1/3/6-month strength leaders
Livermore — Pivotal PointsMulti-touch resistance breakouts
View All Playbooks...
Breakouts
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
Breakouts
WatchlistPricing
Ctrl K
Pricing
GILD
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsCompareWatchlist
GILDGilead Sciences, Inc.
$151.37$187.9B
Overview & Tools
OverviewChart Terminal ↗AnalysisVisualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksGILDP/E History

GILD logoGilead Sciences, Inc. (GILD) P/E Ratio History

Undervalued

Trading at 22.3x vs 5Y avg 88.2x · 65th percentile · Below historical baseline · Data 2001–2026

Current P/E (TTM)
22.3x
-75% vs 5Y avg
5Y Avg P/E
88.2x
Median 18.9x
5Y Percentile
65th
Mid-range
PEG Ratio
0.17
Growth supports price
5-Year P/E Range
22.3x
Min11.9xMedian18.9xMax931.6x
TTM EPS$-2.61
Price$151.37
Earnings Yield4.48%
EPS Growth (1Y)1684.2%
EPS Growth (5Y)133.6%

Loading P/E history...

P/E Ratio Analysis

As of September 24, 2026, Gilead Sciences, Inc. (GILD) trades at a price-to-earnings ratio of 22.3x, with a stock price of $151.37 and trailing twelve-month earnings per share of $-2.61.

The current P/E is 75% below its 5-year average of 88.2x. Over the past five years, GILD's P/E has ranged from a low of 11.9x to a high of 931.6x, placing the current valuation at the 65th percentile of its historical range.

Compared to the Healthcare sector median P/E of 23.7x, GILD is roughly in line with its sector peers. The sector includes 225 companies with P/E ratios ranging from 0.0x to 167.0x.

The PEG ratio of 0.17 (P/E divided by 1684% EPS growth) suggests the stock may be undervalued relative to its earnings growth. Peter Lynch popularized the rule that a PEG below 1.0 indicates an attractive entry point.

Relative to the broader market, GILD trades roughly in line with the S&P 500 median P/E of 25.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.

For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our GILD DCF Valuation Calculator →

Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.

GILD Cross-Benchmark Valuation

How does the current P/E compare to sector peers and the broader market?

vs. Healthcare
22.3vs23.7
-6%
In Line with Sector
vs. S&P 500
22.3vs25.3
-12%
Below Market
PEG Analysis
0.17
P/E ÷ EPS Growth
PEG < 1 = Attractive
Based on 1684% EPS growth (1Y)

GILD P/E vs Peers

Specialty and biologics-focused pharma peers sorted by market cap

CompanyMarket CapP/E RatioPEG RatioEPS Growth (1Y)
ABBV logoABBVAbbVie Inc.
$469B111.9--1%
BMY logoBMYBristol-Myers Squibb Company
$125B17.7Lowest-+178%
AMGN logoAMGNAmgen Inc.
$219B28.59.70+88%
BIIB logoBIIBBiogen Inc.
$34B25.8--21%
REGN logoREGNRegeneron Pharmaceuticals, Inc.
$83B19.33.05+8%
VRTX logoVRTXVertex Pharmaceuticals Incorporated
$131B33.74.07+837%
MRK logoMRKMerck & Co., Inc.
$366B20.30.96Best+8%
PFE logoPFEPfizer Inc.
$161B20.7--4%
JNJ logoJNJJohnson & Johnson
$648B24.41.64+91%
INCY logoINCYIncyte Corporation
$25B19.4-+4173%Best

Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.

GILD Historical P/E Data (2001–2026)

Quarterly P/E ratios calculated from closing price and TTM EPS

QuarterPeriod EndPriceTTM EPSP/E Ratiovs Avg
FY2026 Q1-$139.37$7.3419.0x-63%
FY2025 Q4Dec 31 2025$122.74$6.7718.1x-65%
FY2025 Q3-$111.00$6.4517.2x-67%
FY2025 Q2Jun 30 2025$110.87$5.0222.1x-57%
FY2025 Q1Mar 31 2025$112.05$4.7523.6x-55%
FY2024 Q4-$92.37$0.37249.6x+381%
FY2024 Q3Sep 30 2024$83.84$0.09931.6x+1694%
FY2024 Q2Jun 30 2024$68.61$0.8283.7x+61%
FY2024 Q1Mar 31 2024$73.25$0.36203.5x+292%
FY2023 Q4Dec 31 2023$81.01$4.5018.0x-65%
FY2023 Q3Sep 30 2023$74.94$4.6616.1x-69%
FY2023 Q2Jun 30 2023$77.07$4.3517.7x-66%
FY2023 Q1Mar 31 2023$82.97$4.4318.7x-64%
FY2022 Q4Dec 31 2022$85.85$3.6423.6x-55%
FY2022 Q3Sep 30 2022$61.69$2.6423.4x-55%
FY2022 Q2-$61.81$3.2718.9x-64%
FY2022 Q1-$59.45$3.5716.7x-68%
FY2021 Q4Dec 31 2021$72.61$4.9314.7x-72%
FY2021 Q3-$69.85$5.8611.9x-77%
FY2021 Q2Jun 30 2021$68.86$4.1016.8x-68%
FY2021 Q1Mar 31 2021$64.63$0.23281.0x+441%
FY2020 Q4-$58.26$0.08728.3x+1302%
FY2020 Q3Sep 30 2020$63.19$0.9765.1x+25%
FY2020 Q1-$74.76$3.8919.2x-63%
FY2019 Q4-$64.98$4.2115.4x-70%
FY2019 Q3Sep 30 2019$63.38$2.0930.3x-42%
FY2019 Q2Jun 30 2019$67.56$4.6114.6x-72%
FY2019 Q1Mar 31 2019$65.01$4.5314.3x-72%
FY2018 Q4Dec 31 2018$62.55$4.1615.0x-71%
FY2018 Q3Sep 30 2018$77.21$1.2064.3x+24%
FY2018 Q2Jun 30 2018$70.84$1.6642.7x-18%
FY2018 Q1Mar 31 2018$75.39$2.6029.0x-44%
FY2017 Q4Dec 31 2017$71.64$3.4820.6x-60%
FY2017 Q3Sep 30 2017$81.02$8.789.2x-82%
FY2017 Q2Jun 30 2017$70.78$9.217.7x-85%
FY2017 Q1Mar 31 2017$67.92$9.467.2x-86%
FY2016 Q4Dec 31 2016$71.61$9.947.2x-86%
FY2016 Q3Sep 30 2016$79.12$10.787.3x-86%
FY2016 Q2-$83.42$11.357.3x-86%
FY2016 Q1-$91.86$11.697.9x-85%
FY2015 Q4-$101.19$11.928.5x-84%
FY2015 Q3Sep 30 2015$98.19$10.929.0x-83%
FY2015 Q2-$117.08$9.5312.3x-76%
FY2015 Q1-$98.13$8.8111.1x-79%
FY2014 Q4Dec 31 2014$94.26$7.3812.8x-75%
FY2014 Q3-$106.45$5.6718.8x-64%
FY2014 Q2Jun 30 2014$82.91$4.4718.5x-64%
FY2014 Q1Mar 31 2014$70.86$2.7326.0x-50%
FY2013 Q4-$75.10$1.8341.0x-21%
FY2013 Q3Sep 30 2013$62.87$1.8334.4x-34%
FY2013 Q2Jun 30 2013$51.27$1.7928.6x-45%
FY2013 Q1Mar 31 2013$48.94$1.7927.3x-47%
FY2012 Q4Dec 31 2012$36.73$1.6422.4x-57%
FY2012 Q3Sep 30 2012$33.17$1.6020.7x-60%
FY2012 Q2Jun 30 2012$25.64$1.6515.5x-70%
FY2012 Q1Mar 31 2012$24.43$1.6614.7x-72%
FY2011 Q4Dec 31 2011$20.46$1.7811.5x-78%
FY2011 Q3Sep 30 2011$19.40$1.7311.2x-78%
FY2011 Q2-$20.71$1.6712.4x-76%
FY2011 Q1-$21.24$1.6013.3x-74%
FY2010 Q4Dec 31 2010$18.12$1.6610.9x-79%
FY2010 Q3-$17.81$1.7210.4x-80%
FY2010 Q2Jun 30 2010$17.14$1.6610.3x-80%
FY2010 Q1Mar 31 2010$22.74$1.5714.5x-72%
FY2009 Q4-$21.64$1.4315.1x-71%
FY2009 Q3Sep 30 2009$23.25$1.3017.9x-66%
FY2009 Q2-$23.42$1.2019.5x-62%
FY2009 Q1-$23.16$1.1220.7x-60%
FY2008 Q4Dec 31 2008$25.57$1.0624.1x-54%
FY2008 Q3-$22.82$0.9723.5x-55%
FY2008 Q2Jun 30 2008$26.48$0.9228.8x-45%
FY2008 Q1Mar 31 2008$25.77$0.9028.6x-45%
FY2007 Q4Dec 31 2007$23.00$0.8527.1x-48%
FY2006 Q3Sep 30 2006$17.19$0.4042.8x-18%
FY2006 Q2Jun 30 2006$14.79$0.5328.2x-46%
FY2006 Q1Mar 31 2006$15.56$0.4832.1x-38%
FY2005 Q4Dec 31 2005$13.14$0.4330.6x-41%
FY2005 Q3Sep 30 2005$12.19$0.3435.4x-32%
FY2005 Q2-$11.00$0.3135.3x-32%
FY2005 Q1-$8.95$0.2732.8x-37%
FY2004 Q4Dec 31 2004$8.75$0.2535.0x-33%
FY2004 Q3-$9.35$0.1656.8x+9%
FY2004 Q2Jun 30 2004$8.38$0.1458.0x+12%
FY2004 Q1Mar 31 2004$6.93$0.1449.2x-5%
FY2002 Q4-$4.25$0.0495.5x+84%
FY2002 Q3Sep 30 2002$4.19$0.1138.7x-25%
FY2002 Q2Jun 30 2002$4.11$0.0851.9x-0%
FY2002 Q1Mar 31 2002$4.50$0.0598.0x+89%
FY2001 Q4Dec 31 2001$4.11$0.03120.9x+133%

Average P/E for displayed period: 51.9x

Export Data
Consensus & Technical Research Suite
Open GILD Terminal

GILD Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

GILD Stock Analysis

Bull/bear thesis, analyst target revisions, and earnings execution.

View Analysis

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

25+ years return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

GILD — Frequently Asked Questions

Quick answers to the most common questions about buying GILD stock.

What is GILD's P/E ratio?

Gilead Sciences, Inc. (GILD) trailing twelve-month P/E ratio is 22.3x, based on TTM diluted EPS of $-2.61. The 5-year average P/E is 88.2x and the historical range spans 11.9x to 931.6x.

Is GILD stock overvalued or undervalued?

GILD trades at 22.3x P/E, below its 5-year average of 88.2x. At the 65th percentile of its historical range (11.9x–931.6x), the stock is priced at a discount to its own history.

Is GILD stock expensive?

No, GILD is not expensive on a historical basis. The current P/E of 22.3x is below the 5-year average of 88.2x and sits at the 65th percentile of its valuation range.

What is GILD's historical P/E range?

Over the past 5 years, GILD's P/E ratio has ranged from 11.9x to 931.6x, with a median of 18.9x and an average of 88.2x. The current P/E of 22.3x places the stock at the 65th percentile of this range. Full historical data spans 2001–2026.

How does GILD's P/E compare to the S&P 500?

GILD trades at 22.3x P/E versus the S&P 500 median of 25.3x. The 12% discount to the market suggests lower growth expectations or perceived higher risk.

How does GILD's valuation compare to Healthcare peers?

Gilead Sciences, Inc. P/E of 22.3x compares to the Healthcare sector median of 23.7x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.

What is GILD's PEG ratio?

GILD PEG ratio is 0.17, based on a P/E of 22.3x and EPS growth of 1684.2%. A PEG below 1.0 indicates the valuation is supported by the earnings growth rate — typically considered attractive.

What is GILD's earnings yield?

GILD earnings yield is 4.48%, the inverse of its 22.3x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.

GILD P/E Ratio History (2001–2026)

Quarterly valuation multiple from closing price and trailing EPS

Current19.0x
Period Avg88.2x
Range11.9x - 931.6x
Change+13%
20 quartersJun 30, 2021 - Mar 31, 2026